BSEResult22h ago · 30 Jul 2026, 11:56 am

We have attached herewith financial results for the quarter ended June 30, 2026. Kindly take the same on your record. Thank you.

Anlon Healthcare Ltd · 544497

✦ AI SummaryResults

Anlon Healthcare Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, along with a limited review report. The company has also authorized a share swap arrangement with shareholders of Apiqo Organics Private Limited and Bizotic LifeScience Private Limited to acquire a majority stake in these entities.

Analysis Scores

Earnings Impact6/10
Growth Catalyst4/10
Governance Concern2/10
Regulatory Risk3/10
Balance Sheet Risk5/10
Liquidity Impact7/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Anlon Healthcare Ltd - 544497 - Financial Results For The Quarter Ended June 30, 2026

Attachments (1)

📄

e14c129f-fa7b-4631-9825-fbcea189cde0.pdf

pdf

Download →
View document text
anion July 30, 2026 To, To, Listing Department, The National Stock Exchange of India BSE Limited Ltd. Phiroze Jeejeebhoy Towers, The Listing Department Dalal Street, Exchange Plaza, Mumbai - 400 001 Bandra — Kurla Complex, Ref: BSE Scrip Code: 544497 Mumbai - 400051, NSE Scrip Code: AHCL Sub: Outcome of Board Meeting of ANLON HEALTHCARE LIMITED (“Company”) Respected Sir/Madam, Pursuant to Regulation 30 read with Part - A of Schedule III of SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Thursday, July 30, 2026 at the Registered Office of the Company inter alia considered and approved the following matters: 1. Unaudited Financial Results (Standalone and Consolidated) of the Company as set out in compliance with Indian Accounting Standards ("IND AS") for the quarter ended June 30, 2026; together with the Limited Review Report of the Auditor's thereon. (Enclosed herewith) the Board authorized to Mr. Punitkumar Rasadia, Chairman & Managing Director and/or Mr. Meet Vachhani, Whole Time Director of the Company, for entering into a share swap arrangement with the shareholders of Apiqo Organics Private Limited (“AOPL”) and Bizotic LifeScience Private Limited (“BLPL”) to acquire [32.52%] shareholding in AOPL and [43.33%] shareholding in BLPL, to make both these entities as wholly owned subsidiaries, in lieu of issuance and allotment of the fresh equity shares of the Company on a preferential basis for consideration other than cash, to such selling shareholders. Meeting Commenced on 10:30 a.m. IST and Concluded on 11:30 a.m. IST. You are requested to take the above information on your record. Thanking You. For ANLON HEALTHCARE LIMITED PUNITKUMAR RASADIA MANAGING DIRECTOR DIN: 06696258 ANLON HEALTHCARE LIMITED CIN No.: U24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat (INDIA) PHONE NO.: +91-706969010/882 | Email: info@anlonhealthcare.com | www.anlon.in &Co. I Ren sd ue lp te sn de ofn t theA ud Ci oto mr p' as nyR evi pe uw r suR ae np to rt t o on R egth ue l aQ tu ia or nt er 3l 3 y ofa nd t he Yea Sr E BIto d (a Lt ie s tiU nn ga ud Oi bt le id ga tS it ona sn dal ano dn e DF ii sn ca ln oc si ua rl e Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Anton Healthcare Limited (1) W He lth ha cv ae re Lv ii me iw te ed (t th he 'a Cc oc mo pm ap na yn ’y )i n fg ts ht ea t qe um ae rn tt o ef ndu en da u Jd ui nt ee d 30,s ta 2n 0d 2a 6l o an ne yf ei an ra nc ti oa l atr ee su fl rt os o Af riA ln to 01n 026 to June 30, 2026 (the Statement’), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the ‘Listing Regulations’). (2) T C p p t 3h r r 3o hi i e ems n s rp o c c e fa i r upn iS tnly b ht de eea ' es dt s r e L m il u a se aB n tnn io d iddt a n e, gr r o d d t o h Rw S ew eh o e r gnf ci u tc laiDh acoi i tcnnr i oe oc uis nit n 1n so 3 td .r 3t iis h na,e g On o f u h rr pa A te rs hcs i rep c n eo cob sn iCe u ps pe on oi ln nmtb e si pi s il n ap bi gr n igt e li ey p ine a teS sr yrt o e aaf d ln A i l sd c ytt a ti h ,rn oe d a e ca 2 xcc 0C pec 13o rp4 3om e t,r sp e d s(a da I a n n sny ac d i n ' e a c s m oIA nneSw d cni i ldtM a uh e a 3 sd4n a i) ,t n oa ,h d neg e r‘ iem r oI na ne ne d tc c n eo o tt rg hw mi e n i pm i t l ht Sia i tn aFo ad r nin t en c ela e menaa evcnp a nid wp n ta ir tl t o m hv b e r ae a uR R sd les e ee pu g dsor u rb le ty oi am i ns tn e s ign ut oo’ eh t un, de r review. (3) (W E p m r ar mnSe e i ne e atR r ds s v ti E f ps tit o)c y eo t e c’ rnro a w ss m tn i ed 2 i sb imu 4 s tsl e1 sc ht e anu0 ht s tue, e te u d e. bd f so r r t' itb A e glaR y o v n ye fu i tr ti vr t ie e n i h aaw v dee ln i r ow elcee i yI w sv t a n oi ilso de t f lo enw i ef oo nt a s tbu snI i t t dno e n fa tf i iti e n een a r ao drt ci f bh i s m ce lm c m o iC o nuo h pS fF nda e ait i uter nn sna irt aat tne a nn ae h tgr t c uc oam ie e di ne a id a omln .a t a ttaA ni ats c An ieI sc ci nrf ann uo cs o uf r ou , dro aa i rn mr n tc dt am c a c ia t na eo nn i cdt rr go t oi ad lns no na aa dn s cpn u ec p c o co lfe t tn P wyo s tee eiI hi d r nn aw swd g tfi t di h ot s oa e ih r . wnat m eno nhe f aaT ot e d tlhh cr cye mi c ots a o eui kb xrcS lty i pdas dht rne l a ta ga nn t sbn cd h a sde S ea en a itr dnr ad aqI d t nw mun oe ii ed t tmo r ar h hen ie ue e p en dq r ase itu S, wR tn i t ae rd r a reev e p oni evs rni s pd ii ite aem w t f r owa ih r fdr oa eA sit e nu aplE .d ly r n lwi o oog et nf c sa oo e A ifrg d p u gm e ul ndpa ram ie ito n e fe ref t isn s r i c.oiat at n nans h ngld se tA (4) tB Cl p oh aa froe i s i d m ne Rp cad ead i gc po n uc lo w i lo en n ae s m s po au g oir en n A ny c er ti t rh 3e ,n e a v g li l e 2 oa y f0w p S 1 pt 3 tl a hac ,i c to c c e an em Lb ad pse ilu t sn ec e tt t da i, e m Id gen i n ndp i dr Ra a Ie es en n p d gd aa u, irb la Ae ,o ac dv tc r e iheo, oaaui s ndn n n t ,no a i w ot c n tih c tgi no h dn r ig ld S s ura t c den lh a ila c on nes e sd gv e a a dc r n tw tdo hi sm t et h e h er u( l a"t it eI no h nsn e nd f o eou i rrr Ar se m S sc a’ ua i)o t net g i dt n o e wsi nn hpt t te iii hc croo ei henn f r q i e uet u iia tdh n rna edd it sd e u r tnc m oda t e oeu a a brs en bs e eds u S dr d iee ou sics m t cst he li cet oo lno r sn o t e s b dep ae ,d1rl c 3ii c3 oe n o i rv nc u e i o n t tfp t he l ait r th te n m a hs g st e i t contains any material misstatement. Date: July 30, 2026 For, RV D & Co Place: Rajkot Chartered Acc oun tants ICAI Fir m istration No 143936W hip No 174550 Yom :2 Z| 2455 oF WYOOU HHA. “Level-6",Office No 604-605,Near AP Park, Opp Imperial Heights, Rajkot-360005 +916356 797 885 & 0281 - 2991685 BSA office@cakda.iin @ www-cakdain Anlon Healthcare Limited L24230GJ2013PLC077543 Address: 101/102-Silver Coin Complex, Opp. Crystal Mall, Kalawad Road,Rajkot 360005, Gujarat (INDIA) Standalone Financial Result for the period ended on 30-6-2026 Rs. in Lakhs (Unless stated otherwise) Quarter Ended Year Ended SrNo Particulars 30-6-2026 31-3-2026 30-6-2025 31 March 2026 Unaudited Audited Revenue From Operations 3,097.56 5,542.22 3,329.72 17,649.87 Other Income 5.96 25 1.17 25.39 Total Income (I) 3,103.52 5,543.47 3,330.89 17,675.26 ll |Expenses Cost of materials consumed 2,694.05. 3,323.68 2,959.48 12,976.38 Changes in inventories of finished goods, Stock in Trade and work in -789.16 235.76 -537.18 -1,691.69 Employee benefits expense 152.07 125.16 122.49 525.12 Finance costs 96.36 118.29 82.05 435.29 Depreciation and amortization expense 65.79 13.09 42.68 136.31 Other expenses 294.04 466.34 160.96 1,226.28 Total expenses (II) 2,513.15 4,282.32 2,830.48 13,607.69 Ill |Profit/(loss) before tax (I-Il) 590.37 1,261.15 500.41 4,067.57 IV |Tax expenses Current tax 152.39 148.54 147.91 1,140.03 Deferred tax -41.73 133.41 -2.19 146.72 Total Tax expense (IV) 110.66 281.95 145.72 1,286.75 V_ |Profit/(loss) after tax for the period (IlI-IV) 479.71 979.20 354.69 2,780.82 VI |Other Comprehensive Income OCI that will not be reclassified to P&L -2.31 -7.13 - -6.79 OCI Income tax of items that will not be reclassified to P&L 0.58 1.70 - 1.70 Total Other Comprehensive Income (VI) -1.73 -5.43 - -5.09 Vil. |Total Comprehensive Income for the period (V+VI) 477.98 973.77 354.69 2,775.73 Vill |Earnings per equity share Basic 0.09 0.21 0.09 0.59 Diluted 0.09 0.21 0.09 0.59 For and on behalf of Board of Directors, Anion Healthcare oY. Place: Rajkot ; Date: July 30, 2026 SIGNED FOR |DENTIFICATJON BY RVD&Co, Chartered Accountants FRN 143936W Date. 3@../2A./.2RPZE Place : Rajkot Anion Healthcare Limited L24230GJ2013PLC077543 Notes to the Standalone Financial Result for the period ended on 30-6-2026 C A Pno hlr aop rno m r aa ct eHe ue ta ili ctn h [Showing first 8,000 characters — download PDF for full document]